Challenge
Following Alzheimer’s disease, Parkinson’s disease is the second most common neurodegenerative disorder in the US. LRRK2 is one of the most promising drug targets for Parkinson’s disease. There are currently some drug candidates in clinical trials, but no FDA-approved drug. The goal: to pioneer the first approved therapy in this large and critical market.
Solution & Impact
BIOPTIC B1 model quickly identified a chemically novel 0.86 uM LRRK2 inhibitor from a vast chemical space of 39B molecules. In the second iteration we improved potency 4.4 times achieving 0.19uM. This discovery brings us closer to delivering a best-in-class solution for an underserved patient population.
